Elevated neutrophil-monocyte-to-lymphocyte ratio increases risk of adverse outcomes in patients with chronic kidney disease and type 2 diabetes

中性粒细胞-单核细胞/淋巴细胞比值升高会增加慢性肾脏病合并2型糖尿病患者发生不良预后的风险。

阅读:2

Abstract

BACKGROUND: The relationship between the neutrophil-monocyte-to-lymphocyte ratio (NMLR) and adverse outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes remains unclear. This study explored the association between NMLR, adverse cardiovascular events, and CKD progression. METHODS: This single-center retrospective study included patients with CKD and type 2 diabetes between November 2016 and December 2023. Patients were divided into tertiles according to NMLR values. The primary outcome was major adverse cardiovascular events (MACEs), while the secondary outcome was CKD progression. Restricted cubic splines (RCS) were used to describe the association between elevated NMLR and the risk of adverse outcomes. Cox proportional hazards regression models were used to identify risk factors contributing to poor prognosis. Nomograms were developed to predict event-free survival, with their performance validated using the area under the curve (AUC). RESULTS: A total of 586 patients were included in this study. Over a median follow-up period of 23 months, at least one adverse event occurred in 225 patients (38.4%). The risk of MACEs, CKD progression, or both gradually increased across the NMLR tertiles (21.9% vs. 22.1% vs. 35.4%, p for trend = 0.001; 18.4% vs. 23.6% vs. 30.8%, p for trend = 0.004; and 31.6% vs. 35.9% vs. 47.7%, p for trend = 0.001, respectively). RCS showed an elevated risk of MACEs, CKD progression, or both with increasing NMLR (HR = 1.43, 95% CI [1.20, 1.70]; HR = 1.41, 95% CI [1.23, 1.61]; HR = 1.38, 95% CI [1.23, 1.55], respectively; all p < 0.001). CONCLUSIONS: Increased NMLR was positively correlated with a higher risk of adverse cardiovascular events and CKD progression in patients with CKD and type 2 diabetes, and routine assessment of NMLR, particularly in those above 1.6, may aid in effective risk stratification and early intervention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。